0.0030
-0.0002
(-6.25%)
At close: January 24 at 3:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
92.8980
39.5180
8.8750
60.4600
--
Operating Expense
2,404.6350
2,790.3570
4,661.6470
7,789.0250
4,833.0990
Operating Income
-2,313.4810
-2,750.8390
-4,652.7720
-7,728.5650
-4,833.0990
Net Non Operating Interest Income Expense
-781.3050
-1,204.7640
-1,876.1600
-742.2650
-320.1380
Other Income Expense
-1,041.0870
-4,104.0790
285.9830
-7,553.4790
-1,137.3500
Pretax Income
-4,135.8730
-8,059.6820
-6,242.9490
-16,024.3090
-6,290.5870
Net Income Common Stockholders
-4,135.8730
-8,059.6820
-6,242.9490
-16,032.3050
-6,409.8800
Diluted NI Available to Com Stockholders
-4,135.8730
-8,059.6820
-6,242.9490
-16,032.3050
-6,409.8800
Basic EPS
-0.02
-0.04
-0.04
-0.12
-0.06
Diluted EPS
-0.02
-0.04
-0.04
-0.12
-0.06
Basic Average Shares
255,020.1700
227,691.4520
165,468.2630
131,539.9200
110,386.3860
Diluted Average Shares
255,020.1700
227,691.4520
165,468.2630
131,539.9200
110,386.3860
Total Operating Income as Reported
-2,313.4810
-2,750.8390
-4,652.7720
-13,974.9980
-4,948.9980
Total Expenses
2,406.3790
2,790.3570
4,661.6470
7,789.0250
4,833.0990
Net Income from Continuing & Discontinued Operation
-4,135.8730
-8,059.6820
-6,242.9490
-16,032.3050
-6,409.8800
Normalized Income
-3,169.8660
-4,035.6830
-6,528.9320
-8,470.8300
-5,153.2370
Interest Income
--
--
0.2570
1.0260
0.6750
Interest Expense
781.3050
1,204.7640
1,876.4170
485.8250
320.8130
Net Interest Income
-781.3050
-1,204.7640
-1,876.1600
-742.2650
-320.1380
EBIT
-3,354.5680
-6,854.9180
-4,366.5320
-15,538.4840
-5,969.7740
EBITDA
-2,924.9220
-6,427.8990
-3,940.4060
-13,422.7970
-5,953.7730
Reconciled Depreciation
429.6450
427.0190
426.1260
2,115.6870
16.0010
Net Income from Continuing Operation Net Minority Interest
-4,135.8730
-8,059.6820
-6,242.9490
-16,024.3090
-6,290.5870
Total Unusual Items Excluding Goodwill
-966.0070
-4,023.9990
285.9830
-7,553.4790
-1,137.3500
Total Unusual Items
-966.0070
-4,023.9990
285.9830
-7,553.4790
-1,137.3500
Normalized EBITDA
-1,958.9150
-2,403.9000
-4,226.3890
-5,869.3180
-4,816.4230
12/31/2020 - 9/2/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ENDV Endonovo Therapeutics, Inc.
0.0003
0.00%
RSPI RespireRx Pharmaceuticals Inc.
0.0008
0.00%
TSOI Therapeutic Solutions International, Inc.
0.0003
0.00%
TXTM ProText Mobility, Inc.
0.0010
0.00%
PXMD PaxMedica, Inc.
0.0310
0.00%
PHGUF Pharming Group N.V.
0.9360
0.00%
OCY.SG Oncimmune Holdings plc
0.1410
+4.44%
LIXTW Lixte Biotechnology Holdings, Inc.
0.0213
0.00%
LOBEF Lobe Sciences Ltd.
0.0017
0.00%
RGTPQ RegenETP, Inc.
0.1500
0.00%